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Abstract: Concerns have been raised that the divisions emerging within public health in response
to electronic cigarettes are weakening tobacco control. This paper employed thematic and network
analysis to assess 90 policy consultation submissions and 18 interviews with political actors to
examine the extent of, and basis for, divisions between health-focused actors with regard to the
harms and benefits of e-cigarettes and appropriate approaches to regulation in Scotland. The results
demonstrated considerable engagement in e-cigarette policy development by health-focused actors
and a widely held perception of strong disagreement. They show that actors agreed on substantive
policy issues, such as age-of-sale restrictions and, in part, the regulation of advertising. Points of
contestation were related to the harms and benefits of e-cigarettes and the regulation of vaping
in public places. The topicality, limitations of the evidence base and underlying values may help
explain the heightened sense of division. While suggesting that some opportunities for joint advocacy
might have been missed, this analysis shows that debates on e-cigarette regulation cast a light upon
differences in thinking about appropriate approaches to health policy development within the public
health community. Constructive debates on these divisive issues among health-focused actors will be
a crucial step toward advancing public health.
Keywords: public health; tobacco control; electronic cigarettes; health policy; United Kingdom;
Scotland; advocacy; evidence; policy debate
1. Introduction
Electronic cigarettes (e-cigarettes) or electronic nicotine delivery systems (ENDS), devices that
“heat a solution (e-liquid) to create an aerosol which frequently contains flavourants” [1] and often
nicotine, have received increased public and policy attention since their invention in 2003. Their rapid
proliferation and use by smokers and non-smokers has led to controversial public health and political
debates, with proponents and opponents of e-cigarettes taking different positions on the potential
implications of e-cigarettes and on the appropriate approach to regulation [2–4]. These controversies
extend to organisations and individuals with an interest in public health that have, for decades,
jointly worked to reduce the harms caused by tobacco through political advocacy. Indeed, the tobacco
control community in the UK has been noted for its effectiveness in achieving research-informed policy
change [5], with the UK topping an international ranking of tobacco control for consecutive years [6].
Analysts argue that this success is at least partially attributable to the ability of researchers, advocates,
practitioners, policymakers and journalists to work collectively, despite not always sharing the same
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underpinning values or rationales [7]. Meanwhile, analysis of internal tobacco industry documents
(obtained through litigation cases in the USA) has revealed that the tobacco company Philip Morris
USA initiated “Project Sunrise” from 1994–2006 with the intention of undermining the effectiveness of
the tobacco control community by exploiting differences of opinion [8]. The high-profile and seemingly
profound nature of the disagreements surrounding e-cigarettes [9] suggests that political actors who
previously unified their activities in efforts to improve public health are now increasingly perceived as
divided in precisely the way Philip Morris USA hoped.
While the disagreement on e-cigarettes has been highlighted in previous publications [9–11],
it remains unclear which specific actors disagree, why they disagree, and on what particular aspects
of the debate they disagree. This paper is the first to examine the debate that occurred in the UK,
specifically on the Scottish proposals for e-cigarette regulation, to shed light on the views and positions
of health-focused policy actors. It particularly focuses on analysing agreement and disagreement among
the public health community regarding the harms and benefits of e-cigarettes and the appropriate level
of regulation. While the paper examines policy debates in Scotland, it includes UK and English actors
(since they engaged with the Scottish policy consultation; the UK has devolved powers on health to
its nations, which means that Scotland adopts its own health policy). The UK context lends itself to
studying e-cigarette policy debates, as it is at the forefront of e-cigarette regulation, with many leading
international experts influential in e-cigarette policy and debates [5,12,13]. E-cigarette use is higher and
its advertising is more prevalent in the UK than in neighbouring European countries [14]. a specificity
of Scotland is that, since political devolution in 1999, responsibility for many (though not all) aspects of
e-cigarette regulation lie with the Scottish government and that Scotland has increasingly assumed
public health policy leadership [15]. The analysis in this paper is likely to assist those working to
protect and improve public health in countries around the world to understand e-cigarette debates
in the UK. It may help to highlight potential areas of convergence as well as issues that need further
reflection, thus supporting the development of more constructive conversations.
2. Materials and Methods
To shed light on a recent example of Scottish regulation of e-cigarettes, this article focuses on
the Health (Tobacco, Nicotine etc. and Care) (Scotland) Act of 2016, one of the most comprehensive
pieces of legislation on e-cigarettes passed in the UK [16]. With regard to e-cigarettes, the Scottish
Act introduces age-of-sale restrictions for youth under 18 years of age; a tobacco and nicotine vapour
product retailer register; and restrictions on advertising and promotion, including brand stretching,
sponsorship, free distribution and nominal pricing. The development of the act is summarised in
chronological order in Table 1. It is important to note that in parallel to the Scottish regulation,
the Nicotine Inhaling Products (Age of Sale and Proxy Purchasing) Regulations of 2015 were adopted,
introducing age-of-sale restrictions on e-cigarettes for those under 18 in England and Wales [17].
Table 1. Chronology of the development of the Health (Tobacco, Nicotine etc. and Care) (Scotland) Act
of 2016.
Date Event
10 October 2014 Scottish Government launches a consultation on “ElectronicCigarettes and Strengthening Tobacco Control in Scotland” [18].
October 2014–April 2015 Consultation is open for submissions.
October 2014–April 2015
Meetings between Scottish Government and several political
actors to consult on Scottish Government’s plans to adopt
regulation of e-cigarettes.
May 2015
Scottish Government releases its report on the consultation on
e-cigarettes and tobacco control in Scotland and its response to
the consultation [19].
4 June 2015 The Health (Tobacco, Nicotine, etc. and Care) (Scotland) Bill isintroduced in the Scottish Parliament.




The Health and Sports Committee (designated lead parliamentary
committee) consults with a range of experts on the bill, including
representatives from the commercial sector, third sector/civil
society, e-cigarette user groups, local authorities and
health professionals [20].
The Health and Sports Committee also engages in a wider public
consultation through the use of an online survey, Facebook,
youth events and video blogs [20].
9 November 2015
The Health and Sports Committee publishes a Stage 1 Report on
the Health (Tobacco, Nicotine etc. and Care) (Scotland) Bill,
which demonstrates clear support for the bill [21].
November 2015–February 2016 Several rounds of amendments in the Scottish Parliament.
3 March 2016 The Health (Tobacco, Nicotine etc. and Care) (Scotland) Act of2016 is passed in the Scottish Parliament.
6 April 2016 The Health (Tobacco, Nicotine etc. and Care) (Scotland) Act of2016 receives Royal Assent [16].
2.1. Overview
This study was undertaken as part of a larger mixed methods research project that combined (i)
a documentary analysis of responses to the two consultations in preparation for the act and related
websites, reports, briefings and other documentary data; (ii) a network analysis of the links between
the websites of actors and their positions on elements of e-cigarette regulation, identified in the
documentary analysis; and (iii) a thematic analysis of semi-structured interviews with a range of actors
with an interest in UK e-cigarette policy, conducted after the Health (Tobacco, Nicotine etc. and Care)
(Scotland) Act of 2016 was passed. In this paper, we focus on the analysis of the data for a subset of
actors with a primary interest in health. The study was reviewed by and obtained ethical approval
from the University of Glasgow College of Social Sciences Ethics Committee for Non-Clinical Research
Involving Human Subjects (application number: 400150145).
2.2. Documentary Data Collection
Documentary data were derived from the 2014 Scottish government consultation on its draft paper
“Electronic Cigarettes and Strengthening Tobacco Control in Scotland” and from the 2015 Scottish
Parliament Health and Sports Committee consultation on the Health (Tobacco, Nicotine, etc. and Care)
(Scotland) Bill. Both consultations provided an opportunity to identify key actors in the e-cigarette
regulation debate. Responses were included in the sample if they derived from an organisational actor
(as opposed to an individual), dealt with the regulation of e-cigarettes and were publicly available.
Based on these inclusion criteria, 121 out of 266 consultation responses were selected for inclusion in
the documentary analysis (Figure 1). In addition, key websites (including the Scottish Parliament’s
website, which lists documents related to the policy process; the Scottish government’s website on the
“Consultation on Electronic Cigarettes and Strengthening Tobacco Control in Scotland”; and the Scottish
Parliament’s Health and Sports Committee’s website) were searched to identify other documents of
relevance to the policy process, as well as key individuals and organisations involved in the process
and their positions.
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Non-Health Manufacturers of pharmaceuticals 2 
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Figure 1. Flowchart of selection of consultation documents.
2.3. Identification of Health-Focused Actors
This study focused on examining consultation responses and other documentary data from
organisations with a primary health focus. Health-focused actors were identified as organisations,
charities or representative bodies whose work focused on tobacco control or other public health issues,
the prevention and cure of specific diseases, health research or health service provision. Where it was
not immediately clear whether an organisation could be labelled as health-focused, internet-based
research was undertaken to assess its (or, if this was not possible, its UK/EU umbrella organisation’s)
view on health issues and decide whether to label the respective organisation as health-focused.
Through this process, 90 of the 121 organisations that engaged in the Scottish government consultation
were identified as having a focus on health. Table 2 lists all types of organisations that submitted
responses to the consultation process, differentiating between actors that were labelled as health-focused
(n = 90) and those labelled as non-health-focused (n = 31).
Table 2. Actors who submitted responses to the consultation process.
Focus Type of Organisation Number
Health Third sector/civil society organisations with a specificinterest in health 23
Health Local authorities with remits in health (e.g., healthimprovement, consumers and environment) 21
Health Health service/National Health Service(NHS) organisations 16
Health Organisations representing health professionals 16
Health Academic groups focused on health issues 6
Int. J. Environ. Res. Public Health 2019, 16, 3103 5 of 19
Table 2. Cont.
Focus Type of Organisation Number
Health
Third sector/civil society organisations with interests
in broader health/social issues (e.g., health equality,
children, sports and social care)
4
Health Other organisations with remits in health (e.g., publicbody focused on violence reduction) 4
Total Health-Focused Actors 90
Non-Health Manufacturers of traditional cigarettes 9
Non-Health Retail organisations 6
Non-Health Manufacturers of e-cigarettes 4
Non-Health Manufacturers of pharmaceuticals 2
Non-Health Smokers’ and vapers’ rights groups with knownlinks to the tobacco industry 2
Non-Health Other commercial actors (e.g., advertising industry) 1
Other organisations without a health focus (e.g.,
research organisation with known links to the
tobacco industry)
7
Total Non-Health-Focused Actors 31
Health and non-health Total of all organisational actors submitting responses 121
2.4. Network Analysis
Consultation responses submitted by the 90 health-focused organisations were investigated using
network analysis. Given its ability to investigate network structure and links between different actors,
network analysis was deemed an appropriate tool to explore the extent and appearance of consensus
and dissent between health-focused actors. Each organisation was identified as a node. Attribute data
for each node were systematically extracted from the consultation responses and organisations’
websites, including characteristics with relevance to the research question. These included type of
organisation, primary interest, geographic location, level of engagement in the policy process and the
organisation’s position on each aspect of the proposed e-cigarette regulation. Six pre-set opportunities
for engagement were treated as proxies for the level of actor engagement in the policy process
(Table 3). The chosen events were identified during the documentary analysis as crucial opportunities
seized by interested actors to engage in the process. a thorough search of all policy documents for
attendance at or participation in the respective event by representatives of the 90 health-focused
organisations allowed rating each organisation’s level of engagement. All data were numerically coded
in an Excel spreadsheet.
Web links were used as proxies for the relationships between the health-focused actors and were
identified using the web crawling software IssueCrawler (www.issuecrawler.net). IssueCrawler is
a web network location and visualisation software that crawls specified sites and captures outlinks
from those sites to other specified web sites. The interactor setting of IssueCrawler was used with the
maximum crawl depth possible (three degrees of separation) to extract directed ties between network
actors that were up to “three clicks away”. Manual web crawling was carried out for the small number
of websites that were not accessible to IssueCrawler. Any organisations that did not have a website and
could therefore not be crawled were included in the data file as having no links with any other actor in
the network. All data were treated as non-valued data. All isolates were removed, and the strength
of tie was set to be the same for all relationships before analysing the network. Network analysis
was carried out using the software Gephi (version 0.9.1). In order to analyse the nature and structure
of the network and to identify actors that had important positions within the network as well as
any relevant links between network actors, centrality analyses using eigenvector calculations were
conducted. The Fruchterman–Reingold algorithm and Gephi were used to display the network map.
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Table 3. Opportunities for actor engagement in the policy process: six levels of engagement.
1. Submission of a written response to the Scottish Government consultation process.
2. Attendance of a meeting with Scottish Government officials as part of the consultation process.
3. Attendance of a ministerial working group meeting prior to the publication of the first draft of the Health
(Tobacco, Nicotine etc. and Care) (Scotland) Bill.
4. Submission of a written response on the e-cigarette aspects of the draft Health (Tobacco, Nicotine etc. and
Care) (Scotland) Bill to the Scottish Parliament’s Health and Sports Committee consultation.
5. Provision of oral evidence to the Scottish Parliament’s Health and Sports Committee, the Scottish Parliament’s
Finance Committee or the Scottish Parliament’s Delegated Powers and Law Reform Committee on the draft
Health (Tobacco, Nicotine etc. and Care) (Scotland) Bill.
6. Attendance of a ministerial working group meeting after the publication of the first draft of the Health
(Tobacco, Nicotine etc. and Care) (Scotland) Bill and prior to the adoption of the bill in the Scottish Parliament.
Given the prominence of age-of-sale restrictions, the regulation of advertising and marketing and
the regulation of vaping in public places in the debates, these policy elements were identified as the
most significant and were selected as the focus for a more detailed network analysis. The sociograms
were colour-coded to highlight the position of health-focused actors on each of these three policy areas.
2.5. Interviews
A list of political actors engaged in e-cigarette policy was developed from the documentary
data, which was then used to purposively select and prioritise potential interviewees. Our aim was
to obtain maximum variation in the sample of actors representing different types of organisations,
different positions on e-cigarette regulation and different levels of engagement in the policy process [22].
Potential interviewees were approached by email or telephone invitation. a topic guide was developed
that covered questions on reasons for engagement in the policy process; actors’ interests in, and positions
on, the benefits, harms and regulation of e-cigarettes; actors’ use of evidence; actors’ efforts to shape
e-cigarette policy; and their roles in the policy debate. The interviews typically lasted between 45 and
60 min and were either conducted face-to-face or by telephone, depending on participants’ preferences.
All interviews were recorded and transcribed verbatim. Transcripts were read and reread by the
authorship team prior to developing and agreeing on a thematic coding frame. Each transcript was
coded and analysed using iterative comparisons and the recoding of emergent themes. The principle
of the constant comparative method was used to help identify explanations of patterns across the
data [23]. a total of 25 semi-structured interviews were conducted between October 2016 and
August 2017. The interviews were conducted with a variety of actors who had an interest in Scottish
e-cigarette regulation, including representatives of third sector/civil society organisations with a specific
interest in health (n = 5), the academic sector (n = 4), health service providers (n = 4), health
service/National Health Service (NHS) organisations (n = 3), representatives of manufacturers of
traditional cigarettes (n = 2) and e-cigarettes (n = 2), representatives of local authorities with a health
remit (n = 1), government authorities with a health remit (n = 1), the retail sector (n = 1), manufacturers
of pharmaceuticals (n = 1) and vapers (n = 1). The focus of the qualitative analysis for this paper was
on the interviews with actors that represented organisations with an explicit focus on health (n = 18).
Data from interviews with actors representing organisations that had no explicit health focus (n = 7;
i.e., manufacturers of traditional cigarettes, e-cigarettes and pharmaceuticals; the retail sector and
vapers’ groups) are only drawn on below sporadically to highlight external perceptions of the network,
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overlaps in views or disagreement. In these cases, it is explicitly made clear that other interview
data are being referred to. Interview participants were guaranteed anonymity, and therefore when
reporting interview data, we use a generic descriptor that provides only the professional context of
the speaker. We cannot provide further details on the interviewees. Given that some representatives
of organisations with an interest in health, including individuals that were interviewed as part of
the project, were uncomfortable with the term “stakeholder” because they felt that it suggests that
tobacco companies have a legitimate interest/stake in health policy, it was decided to use the term
“(political) actor” in the project to refer to political actors with an interest in e-cigarettes and to avoid
the term “stakeholder”.
Some supplementary content analysis of the documentary data was undertaken and used to
triangulate the network as well as the interview analysis.
2.6. Limitations of the Study
The study had a number of limitations. First, the case study focused on the policy debate on
e-cigarettes in Scotland. While the UK is perceived to be at the forefront of e-cigarette debates [6],
conclusions about other political contexts must remain tentative. Differences in regulation regarding
the nicotine content of e-cigarettes in the EU and the USA mean that e-cigarette debates might differ
significantly between the USA and the case investigated in this paper. Second, the selection of
interviewees with specific views on the policy might mean that some topics received more attention
in the interviews than others. Using the documentary data analysis, however, considerable efforts
were made to reach a sample that included a wide range of individuals who represented different
organisations, sectors and positions on e-cigarette regulation. Third, the links that were detected using
web crawling might indicate permanent, structural links between the organisations that engaged in
the policy debates, rather than links that were specific to the context of e-cigarette policy. In order to
respond to this limitation, the study used data triangulation with interviews to explore the nature of
political actors’ engagement in the UK policy debates to provide a more comprehensive picture and
achieve a better understanding of the complexity of political engagement.
3. Results
3.1. Engagement of Actors Focused on Health
Of the 90 health-focused organisations that engaged in the e-cigarette policy debates, almost half
had an explicit primary interest in health (n = 42). This included organisations representing different
aspects of the NHS, disease-specific lobby organisations and health professionals. An additional
eight organisations’ primary interest was specifically tobacco control. Other actors included
academic groups and organisations representing the interests of consumers, young people or others.
Sixty-five organisations were located in Scotland, with 48 being local and 17 Scottish national
organisations, 2 were in England, and one was in Wales. Twenty-one were UK-wide organisations, and
one was a European organisation. Most actors (n = 62) had engaged in only one policy engagement
opportunity, whereas two organisations (NHS Health Scotland and Action on Smoking and Health
(ASH) Scotland had seized all six opportunities to engage in the policy process. (In order to distinguish
between the different Action on Smoking and Health (ASH) organisations that operate in the UK,
we use the term ASH Scotland to refer to the Edinburgh-based ASH organisation and ASH (in England)
to refer to the London-based ASH organisation.)
A detailed analysis of the structure of the network of all organisations with an interest in public
health showed that multiple connections existed between the different types of organisations (Figure 2).
In particular, civil society and NHS organisations were well connected, as were NHS organisations and
local authorities. Professional bodies were well connected with other professional bodies as well as
with civil society organisations, whereas pharmacies were almost exclusively linked with professional
bodies, rather than with any other organisational type. The few academics in the network were
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well connected to civil society organisations and also displayed a few links with NHS organisations.
Interestingly, the analysis of the interview data suggested that actors with a focus on health perceived
themselves as a bounded coalition, thus supporting the findings of connectivity identified through the
network analysis. Several interviewees referred to “the community” when referring to the group of
actors with a focus on health.
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Figure 2. Network diagram of connections between health-focused actors (nodes are sized by
betweenness centrality).
NHS Health Scotland, Health Information Services/NHS 24, ASH Scotland and, to a lesser degree,
ASH (in England) emerged as particularly central actors with high betweenness centrality (Figure 2),
i.e., as actors who were connected to other actors that were also highly connected. ASH Scotland’s high
eigenvector centrality scores matched the finding that the organisation had seized several opportunities
to actively engage in the policy process: they were perceived by many interviewees as prominent
lobbyists on Scottish tobacco control policy and seemed to be important actors in the network as well
as in the debate on e-cigarette regulation.
3.2. Disagreement between Health-Focused Organisations
While both the network as well as the thematic analysis showed that health-focused actors were
well linked with each other, the interviewees also reported that considerable disagreement existed
among the community with regard to e-cigarettes. One academic interviewee, for instance, highlighted:
“There is a lot of disagreement about whether electronic cigarettes are positive or negative for public
health. There is a huge amount of disagreement.”
Different interviewees noted that the issue was “divisive” (two researchers, one health professional)
and that debates were “quite polarized” (health professional) and “antagonistic” (researcher).
Highlighting the divisions between health-focused actors, interviewees reported that those engaged in
e-cigarette policy showed behaviour that was viewed as “a bit tribal” (third sector policy professional).
a researcher said jokingly:
“It’s a bit like George W. Bush’s, kind of, ‘You’re either with us or against us.’”
Other interviewees referred to the two “duelling” (health service representative) letters that in
2014 had been sent to Margaret Chan, Director General of the World Health Organization (WHO),
by members of the public health community, outlining arguments for and against the regulation of
e-cigarettes [24,25]. Interestingly, disagreement among actors focused on health was not only described
by members of the community themselves but also seemed apparent to potential opponents of health
advocates, e.g., those with commercial interests. a transnational tobacco company representative,
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for example, highlighted that health-focused actors with an interest in e-cigarette debates could
generally be divided into those who “appear determined to prevent their spread and their uptake”
and the “side of the public health community which supports e-cigarettes”.
Interviewees highlighted that disagreement even existed between high-level organisations that
were formally linked to each other. Groups “that you would’ve thought should have a similar line”
(health professional) were reported as disagreeing on e-cigarette use and regulation. Such disagreement
was also recognised by non-health actors that engaged in the policy debates and was perceived as
confusing, as the following quote by a representative of a pro-e-cigarette campaign group illustrates:
“It just seems bizarre that you can have people at Public Health England with the “right” view of
vaping completely opposed to the Faculty of Public Health with almost polar opposite views of vaping.
And then when you look at the fact that the Faculty of Public Health is actually a faculty within the
Royal College of Physicians which is pro-vaping, you know, the picture just becomes so complicated.”
3.3. Contrast to Previous Agreement within the Public Health Community
The interview analysis suggests that dissent developed fairly recently and was perceived as
specific to the context of e-cigarette policy debates. Representatives of organisations with a health
focus frequently mentioned that the sense of controversy was in stark contrast to the previous unity
that they had perceived to exist on other tobacco control issues: one health professional said:
“It’s usually quite rare on a public health topic that we don’t all generally agree.”
Reflecting on their involvement in tobacco control over the last 20 years, one health professional
concluded that they had “never known an issue to cause the divisiveness that this has caused”.
Similarly, a health service representative highlighted that e-cigarettes had “absolutely divided the
community which was so united”. In this context, the previous joint opposition against transnational
tobacco corporations was identified as a crucial unifying factor. Interviewees observed that the
opposition against transnational tobacco corporations had disintegrated in the context of e-cigarette
debates, resulting in increasing disagreement between public health organisations. An academic,
for example, highlighted:
“Now it’s public health fighting among itself instead of what we used to do, which is we knew who the
enemy was. The enemy was the tobacco industry and that has, you know, the debate has shifted.”
Similarly, a health charity representative reflected on the previous unity in judgement, which,
according to her opinion, had been disrupted by e-cigarettes:
“Because up until now, we had a clear ‘good’ and ’bad’, ’good’ versus ’evil’, ’black’ versus ’white’,
’tobacco - bad’, et cetera. E-cigs have thrown that into significant confusion.”
3.4. Emotive Debates and the Role of High-Profile Actors
The interview data also revealed that e-cigarettes and their regulation were perceived as “a very,
very emotive subject” (representative of a UK health charity), with interviewees reporting that
interactions between different public health actors had been “vicious [ . . . ], insulting [ . . . ] and
rude” (academic), that people had at times been “really quite nasty” (representative of a third sector
organisation), and that those who had been at the receiving end had been “shocked” (public health
professional; health charity representative), “horrified” (public health professional), “quite upset”
(representative of a third sector organisation) and “very distressed” (academic). Interviewees reported
that conflicts had been fought out publicly and had undermined their relationships. a representative of
a UK health charity reported:
“[It] has actually split the tobacco-control field and has actually divided what you might consider
professional friendships. People who have been like that [crosses fingers] on tobacco control are all
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of a sudden completely apart. And it’s become incredibly controversial. It is a situation where all
of a sudden incredibly experienced and well-respected global academics are publicly challenging one
another and often falling out on what is becoming an increasingly partisan basis.”
Some interviewees reported that a few vocal and high-profile individuals who took strong
positions had contributed to the polarisation of the debate. In attempts to stress that they themselves
had not done the same, several interviewees reported that they cultivated good relationships with other
actors with a focus on health, were positioned “in the middle” (health service representative) and took
moderate positions on e-cigarettes and their regulation. In a similar attempt to highlight agreement in
the policy debates, some interviewees stressed that disagreement was not really fundamental and that
opinions were “not as far apart as some people seem to think” (researcher). Instead, they claimed that
any controversies concerned rather peripheral issues and were mainly due to the different emphases
that were placed on different aspects of the debate.
3.5. Consequences of Disagreement
Despite trying to stress areas of consensus, interviewees admitted that existing divisions precluded
actors from working together. As several interviewees recalled, this, in turn, meant that no consensus
statements were developed on e-cigarettes. One public health professional said:
“I don’t remember seeing any sort of, even attempt, to have a consensus statement between public
health groups.”
The lack of consensus among the public health community was broadly viewed as negative, as it
prevented advocacy organisations from building on past coalitions and developing joint positions
on issues to increase their voice, political impact and visibility. Importantly, the existing dissent on
e-cigarettes was perceived as decreasing the public health community’s ability to impact the policy
process, with interviewees reporting that policymakers had found it difficult to make decisions on the
regulation of e-cigarettes in the light of apparent controversies. a health professional highlighted that
it is “impossible to come up with a proper regulation [ . . . ] when so many important groups have
a different opinion on it”. Some interviewees even attributed the varying approaches to regulation
in different UK legislatures and health boards to the dissent among the public health community
and the lack of a clear message on the part of health organisations. Concerns were also voiced in
relation to the confusion among the general public about the harms, benefits and appropriate regulation
of e-cigarettes.
Interviewees also stressed that e-cigarette debates had “hijacked the tobacco control agenda”
(representative of third sector organisation) and had drawn a lot of attention away from other tobacco
control issues, which in turn did not receive the consideration they deserved and needed. The following
academic expressed strong concerns about this:
“The e-cigarette issue is so divisive that a lot of debate is directed towards that. We have a lot of
meetings, a lot of discussion, and I think it takes away from pursuing evidence-based tobacco control,
things like mass media, tax, [ . . . ] smoke-free, smoking cessation services. I think that all of those
things have been damaging because we’ve spent so much time fighting about e-cigarettes.”
On this, interviewees reported that the focus on e-cigarettes had taken funding and attention
away from other areas of tobacco control. a health service representative, for example, highlighted:
“[The e-cigarette debate meant that] loads, millions of pounds [were put] into research that could have,
and would have, gone into tobacco. It’s been a diversionary tactic.”
One health service representative reflected on the relative importance of e-cigarettes and on people
losing perspective, stating:
“[E-cigarettes] are just a tiny bit of the pie, and everyone’s forgotten that there’s a whole cake sitting on
the rest of the table. [ . . . ] But all of the stuff we could be trying to talk about and we could be trying
to get innovative policy on is languishing because there’s so much time being spent on e-cigarettes.”
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3.6. Agreement and Disagreement on the Appropriate Level of Regulation
The majority of health-focused organisations expressed an opinion on all elements of the
e-cigarette regulations proposed by the Scottish government when submitting a consultation response.
Response rates ranged from 66% on the introduction of fines for failing to verify age to 94% on setting
a minimum age of sale at 18 (Table 4).
Table 4. Overall agreement and disagreement with elements of e-cigarette regulation that were








The Minimum Age of Sale for E-Cigarettes should be set at 18. 94% 84 1
AoS regulation should apply to all products, not just those
containing nicotine. 71% 60 4
AoS regulation offence should apply to both retailer
and purchaser. 68% 38 23
Sales of e-cigarette devices and refills from self-service vending
machines should be banned. 89% 80 0
AoS restrictions should also apply to e-cigarette accessories. 69% 50 12
It should be an offence to proxy purchase e-cigarettes. 90% 80 1
There Should be Regulation of Domestic Advertising. 89% 76 4
Regulation of advertising of e-cigarettes should be in addition to
that introduced by the TPD 2. 74% 63 4
Billboard advertising should be banned. 69% 56 6
Leafletting should be banned. 69% 54 8
Brand stretching should be banned. 69% 56 6
Free distribution of e-cigarettes should be banned. 70% 58 5
Nominal pricing for e-cigarettes should be banned. 70% 55 8
Point-of-sale advertising should be banned. 70% 49 14
Events sponsorship should be banned. 70% 58 5
There should be a Scottish Retailer Register for e-cigarette devices
and refills. 74% 58 9
The offences and penalties regarding e-cigarettes should reflect
those already in place for the Scottish Tobacco Retailers Register. 71% 56 8
Use of E-Cigarettes in Enclosed Public Spaces Should
be Banned. 72% 54 11
There should be an age verification policy, “Challenge 25”. 74% 63 4
Penalties for selling e-cigarettes to under-18s should be the same
as for tobacco. 66% 54 5
Sales of e-cigarettes by those under 18 should be prohibited. 70% 10 53
1 Response rate = percentage of actors that expressed a view either in support of or opposition to the proposed
regulation. Balance represents missing or unclear data, i.e., actors not expressing a clear view. 2 TPD = Tobacco
Products Directive. Bold: Elements of regulation that were most prominently discussed in the policy debates.
In the context of the very clear sense of division that interviewees described, the documentary
analysis of consultation responses suggests, somewhat surprisingly, a high degree of consensus among
health-focused actors on many elements of proposed e-cigarette regulation (Table 4). The interview
data suggest that there was uniform agreement that e-cigarettes are a less harmful form of tobacco
consumption than traditional cigarettes.
When focusing on the three main areas of regulation—age-of-sale restrictions, regulation of
e-cigarette advertising and marketing and vaping in public places—agreement seemed to be particularly
high regarding the first and, though to a lesser degree, second regulatory proposal. As the network
analysis illustrates, most health-focused actors agreed that the sale of e-cigarettes to those under
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18 years old should be forbidden. The overwhelming majority of health-focused actors (n = 84, 93.3%)
supported respective regulatory proposals, with only 5 organisations (5.5%) taking no clear position
on the issue and one (1.1%) organisation opposing age-of-sale regulations (Figure 3a). Regarding the
advertisement and promotion of e-cigarettes, there was still considerable agreement, though slightly
less than that regarding age of sale and with point-of-sale advertising emerging as a particularly
divisive issue. While most health-focused organisations (n = 76, 84.4%) supported restrictions on
e-cigarette advertising and marketing, 10 organisations (11.1%) took no clear position, and four
organisations (4.4%) did not support regulation, including ASH (in England), who was a leading policy
actor (Figure 3b). The interview data provided further evidence on controversies that existed with
respect to appropriate advertising regulations. The dividing lines seemed to be between a desire to
inform potential consumers and communicate with smokers about switching to less harmful products
and the wish to prevent tobacco companies from advertising an addictive product to non-smokers and
young people. When arguing against the stringent regulation of advertising, interviewees highlighted
that it was “important to get products known to [ . . . ] potential consumers and to communicate
information on risks and benefits of different products” (academic) and that advertising would allow
those providing e-cigarettes “to speak to the smokers, get them to quit” (academic). Point-of-sale
advertising was highlighted as a particularly important way to allow potential consumers “to know
how to use the devices, [ . . . ] try them in a vape shop, [ . . . and . . . ] get reliable information”
(academic). Interestingly, often the same individuals that provided arguments for allowing some forms
of advertising also acknowledged that safeguards had to be put into place to restrict the advertising of
e-cigarettes to non-smokers. When putting this argument forward, interviewees frequently referred
to well-known tobacco industry strategies to promote their products to vulnerable groups and the
difficulties in enforcing the necessary regulation. One academic said the following:
“The tobacco industry will use [ . . . ] advertising to promote uptake by children ‘cause they wanna
grow their market as much as possible and we don’t want that. So, it’s legitimate to have restrictions
on advertising to children but then very difficult to impose or police.”
One interviewee (an academic) provided a neat summary of the dilemma that health-focused
actors seemed to face when trying to develop an opinion about e-cigarette advertising:
“That’s incredibly complex because the evidence isn’t really there. [ . . . ] You want to be able to communicate
with smokers, but you don’t actually want to get a whole load of non-smokers onto e-cigarettes.”
While the analysis of consultation responses suggested a fairly high level of agreement between
health-focused actors with regard to age-of-sale regulation and restrictions on advertising, the issue
of banning vaping in public places was more divisive. Only 54 organisations supported banning
vaping in public places (60.0%), 25 organisations did not take a clear position (27.7%), and 11 (12.2%)
organisations opposed such regulation (Figure 3c). Interestingly, England-based pharmacies and health
professionals, health charities and all ASH organisations (in Scotland, England and Wales) did not
support a ban of vaping in public places.
Contentious debates also seemed to emerge around the harmfulness of nicotine as a drug that was
inhaled when using e-cigarettes. Many actors concluded that smokers, who were the intended audience
for e-cigarettes, would benefit from switching to e-cigarettes, which allowed them to ensure nicotine
intake while avoiding consuming the other harmful substances contained in traditional cigarettes.
Others stressed concerns about continuous nicotine consumption. There was also some debate about
the scope of e-cigarettes to increase cessation and help smokers quit. While many focused on the
potential of e-cigarettes in helping smokers stop smoking, it was also highlighted that they had to be
considered as part of a much broader tobacco control strategy. In fact, a number of interviewees voiced
doubts as to whether e-cigarettes would have a substantial impact on ending the smoking epidemic.
As the following quote by one third sector professional illustrates, these interviewees stressed that
some e-cigarette supporters, notably vapers, were prone to exaggerate the likely impact of e-cigarettes:
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“I mean, there are people who think that they’re some kind of a magic bullet which will solve the
tobacco epidemic . . . .”
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Several public health advocates cautioned against e-cigarettes because they hypothesised that
they might provide a gateway into traditional smoking for non-smokers and particularly for young
people, encourage dual use and contribute to the renormalisation of smoking. Arguments here centred
on the imitation of smoking-like behaviour, public visibility and the subsequent potential acceptance
of e-cigarettes. These arguments were particularly highlighted when talking about regulations of
advertising and promotion and vaping in public places. E-cigarette marketing was compared to
marketing alcopops, which was perceived as the promotion of a product that would be “appealing to
youngsters [ . . . ] where you are encouraging experimentation” (health professional). a government
representative voiced “fears that tobacco manufacturers will hijack this technology and use it to nurture
and gain new smokers [ . . . and to . . . ] get kids hooked on nicotine through this legal means, and then
[ . . . ] they can sort of move to become smokers”. In this respect, the lack of safety and the addictive
potential of nicotine were also important areas of concern.
3.7. Reasons for Disagreement
The analysis suggested that a number of factors shaped the disagreements on e-cigarettes,
including (i) the topicality, changing nature and popularity of the issue; (ii) the lack of evidence on
e-cigarettes; and (iii) the underlying values and views that influenced advocates’ positions.
Interviewees highlighted that e-cigarette debates had taken place in a rapidly changing context,
as new products were developed, companies merged, and the market moved “at a huge fast pace”
(health professional). The dynamics of the market posed challenges to advocates, who reported
that they struggled to keep pace with what seemed like a moving target. The rapid proliferation of
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e-cigarettes and the huge media interest in them were highlighted by several interviewees as crucial
factors that shaped public and regulatory debates. Media reporting was often perceived as unhelpful.
Advocates said that they had been approached by the media to comment on e-cigarettes and reported
that they had perceived journalists as trying to set up a controversial debate and backing them “into
a position that we wouldn’t favour” (representative of a third sector organisation). While health actors
reported that they tried to refrain from promoting simplistic viewpoints or making statements that
were not backed up by sufficient evidence, they acknowledged that this was difficult given the media’s
desire for catchy headlines. Interviewees complained that “media reports [ . . . ] tend to focus on the
extreme aspects of the kind of overarching headlines, rather than the detail” (health professional),
and that the lack of detail in media reporting had increased controversies among those who had
been cited.
Interviewees reported that responding to information requests about e-cigarettes, agreeing on
public statements and developing joint positions on policy proposals had been particularly difficult
because of the lack of evidence on the harms and benefits of e-cigarettes. One health charity
representative postulated that any strong positions on the subject were not justified:
“Anyone that takes a really strong stance on e-cigarettes is wrong, because the evidence is not there
yet to take a strong stance.”
Unsurprisingly, inconclusive evidence seemed to be even more of a problem for organisations
with a commitment to evidence-informed policy. Representatives of organisations that were
focused on research highlighted that their positions had to be based on the best available evidence.
They were concerned that inconclusive evidence had caused problems in developing, agreeing on and
communicating a clear message to policy audiences and also in legitimising their engagement in the
debate: one health charity representative said:
“One of the challenges of an organisation like ours is that everything we have a policy on must have an
evidence base. The very essence is: What is the data? What is the evidence? What firm conclusions . . . ?”
In light of the inconclusive evidence, it might not be surprising that the interview data, in fact,
provided some indication that the positions of health-focused actors on e-cigarette policy were not
necessarily and primarily influenced by the available evidence. They were also informed by personal
experience, normative ideas and views on the primary aims of public health policy and deep-rooted
values about public health. An academic, for example, referred to “entrenched views and values”
(academic) that influenced the policy debates. Other interviewees mentioned firmly held beliefs,
values and views which they perceived as inflexible and deeply rooted in people’s self-image and their
previous experiences of working in, and advocating for, public health. Reflecting on the origin of these
values, selected interviewees reported that the tobacco industry’s history of deception had caused
immense reluctance on the part of some members of the public health community to engage with
commercial actors producing e-cigarettes or consider anything that the industry promoted. A health
service representative highlighted:
“Some people [ . . . ] feel very, very strongly. And it’s all, it‘s very much tied in with their, you know,
personal feelings around the tobacco industry.”
Interviewees who were less opposed to working with companies manufacturing e-cigarettes
(which often also manufactured traditional cigarettes) perceived this opposition to transnational
tobacco companies as a barrier to reacting flexibly to the quickly changing e-cigarette market, to having
constructive policy debates, to considering opposing views and the evidence that informed them,
to building coalitions and eventually to developing and implementing pragmatic policy solutions.
The same interviewees often argued that those who were dealing with smokers on a regular basis and
were thus confronted with the harms caused by traditional tobacco were more likely to be in favour of
e-cigarettes as pragmatic and potentially life-saving quit aids. They contrasted their own approaches
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to harm reduction with those of actors who were not confronted with the suffering of smokers and
thus less likely to support e-cigarettes as a means to reduce harm. However, this hypothesis was
not supported by the consultation data, which showed that it was equally likely for health service
providers, including representatives of health professionals, and for other health-focused actors to
support high levels of regulation, including regulation on e-cigarette advertising and marketing as
well as restrictions on use in public places.
4. Discussion
Drawing on the Health (Tobacco, Nicotine etc. and Care) (Scotland) Act of 2016 as a recent case of
e-cigarette policy development within the UK, this paper is the first to provide an in-depth analysis of
debates on e-cigarette regulation. The paper not only sheds light on the views and positions of key
actors with an interest in the development of e-cigarette policy but highlights common ground as well
as crucial areas of contestation and issues that might require further attention by those interested in
advancing public health. The analysis shows that representatives of health-focused organisations,
including third sector/civil society organisations, local authorities, organisations representing the
health service and health service providers, academic institutions and others, had a strong interest and
made extensive efforts to actively engage in the policy debates. It also shows that organisations that,
in the context of previous tobacco control policy debates, had pursued common goals and aligned key
messages [26] were divided with regard to their assessment of the harms and benefits of e-cigarettes as
well as on aspects of e-cigarette regulation, including vaping in public places and, to a lesser degree,
the promotion of e-cigarettes. This resulted in an inability to build coherent coalitions and to jointly
advocate for specific policy approaches.
A detailed analysis of the disagreements also indicates that most health-focused organisations
supported age restrictions on e-cigarette sales and were in some agreement on the regulation of
e-cigarette advertising. This suggests that political actors could have chosen to focus on developing more
unified positions around age-of-sale and advertising restrictions and may have missed an opportunity
for building an advocacy coalition to influence policy. Our data suggest that, instead, actors frequently
emphasised the areas of policy on which they disagreed. While our analysis outlines that there were
differing views among health-focused actors about aspects of e-cigarette regulation and that this
contributed to a sense of division, the question is why political actors with an interest in health did not
focus on common ground. Comparing this case study of e-cigarette policy to other issues of tobacco
control policy, we can see that there have often been different views within public health about specific
aspects of tobacco control regulation [7,27,28], but also that these disagreements have not undermined
tobacco control coalitions in the same way that e-cigarette legislation appears to have done. It is
important, therefore, to consider why debates about e-cigarettes have proven so divisive.
Our paper provides some indication that in the context of Scottish e-cigarette policy,
the preoccupation with areas of disagreement was exacerbated by the following closely related
factors: (i) the lack of conclusive evidence on the harms and benefits of electronic cigarettes; (ii) the
lack of evidence regarding the effects of regulation; (iii) differing underlying views on appropriate
approaches to health policy development; (iv) the sudden emergence and rapid proliferation of
e-cigarettes and the fast pace of technological change (which meant emerging evidence was often
incomplete or out of date and sometimes conflicting); and (vi) the huge media interest in the e-cigarette
debate. This media attention resulted in frequent requests for academics and political actors to
make public statements. As a consequence, actors with an interest in the debate often, deliberately
or unintentionally, positioned themselves in more polarised positions, which sometimes seemed
influenced primarily by views and opinions rather than evidence. The lack of conclusive evidence,
partially caused by a lack of rigorous clinical trials on e-cigarette use and missing evaluations of policy
interventions, might have made actors more inclined to make statements that were influenced by
personal opinions. It could be argued that this inclination might also have previously contributed to
public dissent among health-focused actors about a report published by Public Health England [29].
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The report, which claimed that e-cigarettes are 95% less harmful to one’s health than normal cigarettes,
was criticized by major international health journals for basing its claims on a study that had major
methodologic limitations, for not acknowledging the potential conflicts of interests of those involved
in judging the harms of e-cigarettes and for failing to meet basic evidentiary standards [2,30,31].
The media representation of actor positions on other public health policy debates, such as the case
of the UK Soft Drinks Industry Levy, provides another example of similar dynamics in light of
inconclusive evidence [32]. Here, Hilton et al. [32] found that there were inconsistencies in the way
actors communicated their support for the policy in public statements, which arose from insufficient
clarity on the nature of the problem and conflicting policy priorities; leaving the actor’s degree of
support open to interpretation.
In addition to the inconclusive evidence on the harms and benefits of e-cigarettes and the
effects that would be expected in case of regulation, views on transnational nicotine and tobacco
companies seemed to hinder the development of consensus among health-focused actors. The fact
that these companies had become major actors in the e-cigarette market, i.e., in the market of products
that some actors perceived as effective quit aids, meant that some actors felt that they needed
to re-consider their views about tobacco companies’ engagement in harm reduction, with some
concluding that tobacco companies should be treated as legitimate stakeholders. Other actors,
however, continued to oppose tobacco industry engagement in health policy and were concerned
that e-cigarettes provided the long-sought-after industry opportunity to “address tobacco industry
delegitimisation” and “ensure the social acceptability” of tobacco companies [8]. Their underlying
views on the need to exclude this industry from e-cigarette debates in order to protect public health
took precedence over seeking consensus with other health-focused actors on the appropriate level of
e-cigarette regulation. This situation seemed to result in dissent and was in contrast to the previously
uniform reluctance of most health-focused organisations to engage with any tobacco industry-affiliated
actors [26]. Shifting positions on tobacco industry legitimacy seemed to result in the loss of a sense
that tobacco control was united by its common “enemy”, a previously important glue and coalescing
force that had held the public health community together in tobacco control debates [7,26,33]. It also
meant that dissent evolved within the health community rather than between actors with an interest
in health and actors with an economic interest, much as Philip Morris USA had tried to achieve via
“Project Sunrise” between 1994 and 2006 [8]. Negative consequences included the disengagement of
experts from the debates and the disruption of professional friendships and collaboration, but more
importantly, an inability to build advocacy coalitions and jointly lobby on a specific approach to
regulation. This helps explain why, although most interviewees positioned themselves as occupying
a “middle ground” on e-cigarettes, few felt that the polarised nature of the debates allowed voices
from the middle ground to emerge or be heard. Interviewees generally agreed that this was likely to
contribute to confusion and uncertainty among public and policy audiences.
The analysis provides some indication that divisions were also influenced by underlying priorities
regarding how to improve public health. It suggests that those with a harm reduction viewpoint were
more likely to focus on supporting individual smokers in quitting and thus opposed the stringent
regulation of e-cigarettes, whereas those with a stronger focus on the social and political determinants of
health and the prevention of smoking uptake, notably among children and young people, seemed more
likely to be critical of e-cigarettes and the marketing strategies of transnational tobacco companies and
more likely to be in favour of stringent regulation.
Our study highlights a number of research areas that could usefully contribute to our understanding
of e-cigarette and public health policy. First and foremost, comparative research could help to develop
a better understanding of why e-cigarette debates are experienced as, and perceived to be, so divisive
compared to other issues of tobacco regulation in which there have been differing views within public
health. Such research could investigate the reasons for disagreement identified in this case study
in more detail, including health-focused actors’ views on the engagement of tobacco and nicotine
companies in e-cigarette policy, or the high media interest and dynamic nature of a policy issue.
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Further analysis of how evidence was understood, framed and employed within the debate on Scottish
e-cigarette policy could help illuminate our understanding of the role of evidence in policymaking.
In order to shed light on any vested interests among health-focused actors and the potential impact
such interests have on health policy debates, it would be valuable to examine conflicts of interests
among actors who engage in e-cigarette debates and investigate how health-focused actors with
a conflict of interest (e.g., some academics, actors who receive commercial sector funding, pharmacists
or other health professionals whose profits at least partly depend on e-cigarette sales) frame the debates.
Finally, research that examines other, including more recent, cases of e-cigarette policies could help to
establish whether any coalitions emerge around areas of consensus and could thus provide important
insights into whether, and if so, how, public health actors are beginning to form alliances and promote
consensual positions in e-cigarette policy debates.
5. Conclusions
The 2016 Scottish case study presented in this paper shows that actors with an interest in e-cigarette
policy struggled to constructively respond to a lack of evidence and evident disagreements on the
harms, benefits and appropriate approaches to e-cigarette regulation. Our analysis also suggests
that some opportunities for building consensus, particularly with regard to age-of-sale regulations,
may have been missed. The paper illustrates how the previous unity among public health actors on
tobacco control issues broke down to some extent as a result of these struggles. The case study also
shows that public displays of division and conflict were perceived by public health actors to have had
detrimental effects on tobacco control in terms of the community’s credibility and policy influence.
Debates on e-cigarettes have developed considerably since the adoption of the Health (Tobacco,
Nicotine etc. and Care) (Scotland) Act. Recent reports have suggested that some degree of agreement
has formed among the public health community with regard to the usefulness of e-cigarettes in
helping smokers quit and reducing the harms of smoking. The National Institute for Health and Care
Excellence (NICE) guidance on e-cigarettes [34], a Scottish consensus statement that was published
by Health Scotland and endorsed by various Scotland-based third sector, research and health service
organisations [35], as well as the ASH report “Smoking Still Kills”, which was endorsed by over
120 organisations [36], provide evidence of consensus on this aspect of e-cigarette use. Other reports
published in recent years have shown that health-focused actors have begun to reflect on some of the
issues that have been identified as controversial in this paper, including the need for building a solid
evidence base on the harms and benefits of e-cigarettes and on the effects of e-cigarette regulation [36,37];
the need to strike a balance between seizing the potential of e-cigarettes in helping smokers improve
their health and minimising the risk of e-cigarette uptake by non-smokers, particularly young
people and children [36,37]; and the special role of tobacco companies in the e-cigarette debates [38].
Constructive and respectful debates among those with an interest in advancing public health on these
divisive issues will be a crucial step toward positive collaboration and creating a uniform public
appearance. While disagreement about key issues continues to exist, those aiming to advance public
health policy might want to highlight aspects of e-cigarette use and regulation they agree on in order
to promote public health.
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